Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

February 9, 2018: By Jon Swedien
Eylea

Eylea

Net sales of Eylea (aflibercept) in the US totaled $975 million in Q4-2017, a 14 percent increase over Q4-2016 revenues of $858 million, Regeneron reported Feb. 8.

The Tarrytown, New York, company reported that net sales of Eylea for the full year were $3.7 billion, an 11 percent increase over the 2016 total.

Bayer commercializes Eylea outside the US. Its net sales of Eylea outside of the US in Q4-2017 were $637 million, a 28 percent increase over the Q4-2016 total, Regeneron said.

Net sales outside the US for the full year were more than $2.2 billion, a 19 percent increase over the 2016 total of $1.9 billion, Regeneron said.

Regeneron recognized $231 million in Q4-2017 from its share of net profit from Eylea sales outside the US, up from $165 million in Q4-2016. For the full year, Regeneron recognized $802 million, up from $649 million in 2016.

Regeneron posted $1.6 billion in revenues in Q4-2017, compared with $1.2 billion in Q4-2016, a 29 percent increase.

The company posted $5.9 billion in revenues for all of 2017, a 21 percent increase over the $4.9 billion it posted in 2016.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility